Concurrent Use of Ambien (Zolpidem) and Methadone

Introduction to Risks and Precautions

The American College of Physicians and other medical guidelines recommend that concurrent use of zolpidem and methadone carries significant risk of respiratory depression and death, but may be necessary in select patients with opioid use disorder and insomnia when non-pharmacologic interventions have failed, requiring extreme caution, use of the lowest effective doses, close monitoring, and naloxone co-prescription 1, 2

The combination of methadone with any CNS depressant, including zolpidem, substantially increases the risk of profound sedation, respiratory depression, coma, and death 1, 2
There is a 3- to 10-fold increased risk of fatal overdose compared to opioids alone when combined with sedatives, according to the National Comprehensive Cancer Network 3, 4
The FDA has issued a black box warning about serious effects from combining opioids with medications that have sedating effects, including slowed or difficult breathing and death 1, 2

The National Comprehensive Cancer Network recommends using the absolute lowest effective dosages of both medications when concurrent use is deemed necessary 3, 4
Prescribe minimum durations of concomitant use and start zolpidem at the lowest available dose (5 mg for women, 5-10 mg for men) and avoid exceeding this, as recommended by the MMWR 5
Maintain stable methadone dosing—do not adjust methadone for insomnia symptoms, according to Praxis Medical Insights 6

Check the Prescription Drug Monitoring Program (PDMP) for other controlled substances the patient is receiving, as recommended by JAMA and Praxis Medical Insights 7, 3
Involve pharmacists and pain specialists as part of the management team, according to JAMA and Praxis Medical Insights 7, 3
Prescribe naloxone with instruction in its use for overdose reversal, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2, 4

Elderly patients (≥65 years) have substantially increased overdose risk, cognitive impairment, falls, and fractures due to altered pharmacokinetics and reduced clearance, according to Praxis Medical Insights 3, 4
Patients with respiratory compromise, such as COPD, asthma, or sleep apnea, are at heightened risk of respiratory depression, according to Praxis Medical Insights 3, 4

Cognitive behavioral therapy for insomnia (CBT-I) is evidence-based and should be first-line, according to JAMA and Praxis Medical Insights 7, 3
Sleep hygiene education, including consistent sleep schedule, avoiding caffeine/screens before bed, optimizing sleep environment, is recommended by the National Comprehensive Cancer Network 1
Mindfulness and relaxation techniques are also recommended, according to Praxis Medical Insights 6
Trazodone 25-200 mg can be used for short-term insomnia management without abuse potential, as recommended by Praxis Medical Insights 6
Hydroxyzine can be used as a non-benzodiazepine alternative, according to Praxis Medical Insights 3

Never prescribe zolpidem for long-term use—it is intended for short-term treatment only, as recommended by the MMWR 5
Do not increase methadone dose to address insomnia—this increases overdose risk without addressing the underlying sleep disorder, according to Praxis Medical Insights 6
Avoid prescribing additional CNS depressants during concurrent therapy, as recommended by Praxis Medical Insights 6
Never assume tolerance eliminates risk—respiratory depression risk persists even in opioid-tolerant patients, according to the National Comprehensive Cancer Network 1, 2